Decode News AI
简体繁體

CVS Study Finds GLP-1 Drugs Need $350 Monthly Cap to Break Even

2026-11-17 10:45 EST · AI-compiled · 287 words · about 1 min · Views …

WOONSOCKET, R.I. - A real-world study released by CVS Health on Nov. 15 found that popular GLP-1 weight-loss and diabetes drugs reduce hospital visits, yet fail to offset higher pharmacy bills for insurers at current prices. Researchers concluded a monthly price near $350 over three years is required to balance total medical spending.

Aetna Claims Show $9,400 Savings Offset by $13,300 Drug Costs

Analyzing 60,000 commercial Aetna patient records across up to three years, CVS Health found GLP-1 medications cut emergency room visits by 10% to 12% during the first two years. Among 4,000 patients remaining on therapy for three full years, hospitalizations dropped 34% to 42%. However, Reuters reported from Aetna data that insurers saved $9,400 per person in medical bills while spending $13,300 more on prescriptions, adding $3,900 in net costs.

Direct Cash Pricing Signals Room for Lower Insurer Rates

While GLP-1 list prices exceed $1,000 monthly, manufacturers Eli Lilly and Novo Nordisk offer direct-to-consumer options for uninsured buyers between $149 and $449 per month. "Researchers concluded that a monthly price of $350 over three years would balance out the costs and benefits of the drugs, though the savings would depend on how healthy or sick a person is," LiveNOW from FOX reported on Nov. 15. Chief Medical Officer Dr. Amy Compton-Phillips noted direct pricing shows drugmakers can profit below $350 monthly.

Expanding Eligibility Fuels Employer Health Plan Affordability Debate

According to CVS Health, more than 137 million U.S. adults are medically eligible for semaglutide therapies. As clinical indications broaden into cardiovascular, liver, and kidney diseases, employers and pharmacy benefit managers face mounting pressure to negotiate steeper rebates.

Sources

Found a factual error or typo? Tell us

Follow Decode News AI on Telegram

Live updates: every new story is pushed the moment it publishes — dozens a day, no digest delay.

@decodenewsai · Subscribe now

Free · unsubscribe anytime

Comments